Needham analyst initiated coverage on TransMedics Group (TMDX), a medical technology company revolutionizing organ transplantation with its Organ Care System (OCS). The analyst sees significant growth potential in the underpenetrated organ transplant market, driven by the company’s National OCS Program (NOP) and innovative OCS technology. The analyst predicts TransMedics will become profitable in 2024 and sees rapid improvement in operating margin, EPS, and cash flow in 2025-2026.